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Abstract
Background: In vivo CD8+ cell depletions in pathogenic SIV infections identified a key role for cellular immunity in 
controlling viral load (VL) and disease progression. However, similar studies gave discordant results in chronically-
infected SMs, leading some authors to propose that in natural hosts, SIV replication is independent of cellular 
immunity. To assess the role of cellular immune responses in the control of SIV replication in natural hosts, we 
investigated the impact of CD8+ cell depletion during acute SIV infection in AGMs.
Results: Nine AGMs were infected with SIVagm.sab and were followed up to day 225 p.i. Four were intravenously 
infused with the cM-T807 antibody on days 0 (50 mg/kg), 6, and 13 (10 mg/kg, respectively) post infection (p.i.). CD8+ 
cells were depleted for up to 28 days p.i. in peripheral blood and LNs in all treated AGMs. Partial CD8+ T cell depletion 
occurred in the intestine. SIVagm VLs peaked at similar levels in both groups (107-108 RNA copies/ml). However, while 
VLs were controlled in undepleted AGMs, reaching set-point levels (104-105 RNA copies/ml) by day 28 p.i., high VLs 
(>106 RNA copies/ml) were maintained by day 21 p.i. in CD8-depleted AGMs. By day 42 p.i., VLs were comparable 
between the two groups. The levels of immune activation and proliferation remained elevated up to day 72 p.i. in CD8-
depleted AGMs and returned to preinfection levels in controls by day 28 p.i. None of the CD8-depleted animals 
progressed to AIDS.
Conclusion: CD8+ cells are responsible for a partial control of postacute viral replication in SIVagm.sab-infected AGMs. 
In contrast to macaques, the SIVagm-infected AGMs are able to control viral replication after recovery of the CD8+ T 
cells and avoid disease progression.
Background
African non-human primates (NHPs) have been infected
with SIV for tens of thousands of years and this long term
infection has resulted in the co-existence of virus and
host [1,2]. The mechanisms by which African NHPs, such
as AGMs, SMs and mandrills, prevent SIV disease pro-
gression to AIDS are not completely understood. During
the recent years, data have rapidly accumulated in this
field allowing the characterization of the pathogenesis of
SIV infection in natural hosts. These studies have estab-
lished three quintessential characteristics of SIV infection
in natural hosts. First, the lack of disease progression is
not due to an exquisite control of viral replication, as SIV
VLs in chronically-infected African NHP hosts are in the
same range or higher than in HIV-infected patients [3,4].
However, in contrast to pathogenic SIV and HIV infec-
tions, during chronic SIV infection in natural hosts, VLs
are remarkably stable for long periods of time, suggesting
an immune control of viral replication. Second, the lack
of disease progression is not due to a lack of pathogenic-
ity of SIVs in their natural host, as there is a significant
depletion of peripheral and mucosal CD4+ T cells during
the acute phase of infection [5]. However, in stark con-
trast to pathogenic SIV and HIV infections, CD4+ T cells
are then restored during the chronic SIV infection in nat-
ural hosts [5]. Peripheral CD4+ T cells rebound to near
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pre-infection levels [2-10]. In the intestine, however,
CD4+  T cells are only partially, albeit significantly,
restored [5]. Finally, natural hosts of SIVs have signifi-
cantly lower levels of CD4+ CCR5+ cells in blood, LNs,
and mucosal tissues [1]. This may significantly impact the
homing of activated, memory CD4+ T cells to the intes-
tine and, as a consequence, the efficacy of mucosal trans-
mission of SIVs in these species [1,11]. Altogether, these
characteristics define the paradox of SIV infection in nat-
ural hosts in which, in spite of low levels of cells suscepti-
ble to SIV infection (CCR5+ CD4+ T cells), there is a
robust viral replication which does not substantially
affect the homeostasis of CD4+ T cells. During the recent
y e a r s ,  b a s e d  o n  t h e s e  r e s u l t s ,  a  n e w  p a r a d i g m  o f  S I V
infection occurred, in which the preservation of CD4+ T
cells in natural hosts is mainly due to their ability to
maintain normal levels of T cell immune activation, pro-
liferation, and apoptosis [2,5,10,12,13]. This paradigm is
supported by our recent observation that induction of
immune activation in natural hosts of SIVs results in sig-
nificant increases of CCR5 expression by CD4+ T cells,
which fuel viral replication and result in CD4+ T cell
depletion [14]. Therefore, the current view is that the
control of immune activation and cell proliferation in
SIV-infected natural hosts is the main factor behind pro-
tection from disease progression [2,15]. It is also known
that depletion of CD20 cells in AGMs does not alter the
course of virus replication or cause the AGMs to progress
to AIDS, thus indicating that humoral immune responses
are not vital in controlling virus replication in natural
hosts [16].
There are several lines of evidence, accumulated from
the study of pathogenic infections that cell-mediated
immune responses may control HIV and SIV replication.
Thus, numerous studies have reported that HIV and SIV
"elite controllers" that effectively control viral replication
and disease progression [17-22] have preserved func-
tional CD8+ T cell response against lentiviral proteins
[17-19]. CD8+ cell depletion studies in RMs during the
acute and chronic SIV infection have led to significant
increases in SIV VLs and rapid disease progression [23-
26]. Moreover, vaccine studies that have demonstrated
protection in RMs challenged with pathogenic SIV
strains have utilized CD8+ depletion to identify the fac-
tors responsible for protection against the challenge
virus. In these studies, the depletion of CD8+ T cells
resulted in increased viral replication of either the chal-
lenge strain or the vaccine strain [27-33]. Finally, the
importance of CD8+ cells in lowering VLs during antiret-
roviral therapy has also been reported in SIV-infected
RMs [34,35].
In spite of the overwhelming evidence of the active role
that CD8+ cells may play during SIV infection in RMs, the
role of immune responses in controlling SIV infection in
natural hosts is still under debate. It has been shown in
AGMs that there is a variable CD8+  T cell response
against SIV antigens such as Gag and Env [36,37]. During
acute SIVsmm infection, SMs showed lower CD8+ T cell
proliferation compared to RMs, which was interpreted as
evidence that SMs do not have robust T cell responses
[38]. Moreover, in chronically infected SMs, the same
group reported that the control of viral replication is
independent of cellular immune responses [39]. However,
another group reported that a correlation can be estab-
lished between the SIVsmm-specific CD8+  T cell
responses and VLs, arguing that CD8+ T cells do play a
role in natural host species [40] and that cytotoxic T lym-
phocyte escape mutations occur during SIVsmm infec-
tion in SMs, pointing to a role of cell-mediated immunity
in controlling viral replication [41,42]. Immune cell
depletion studies also reported contradictory results. In
one study it was reported that in vivo CD8+ cell depletion
had no impact on SIV replication in SMs. In that study,
increases in viral replication were observed after CD8+
cell depletion, but the authors interpreted them as being
related to increases in activated and proliferating CD4+ T
cells rather than to the ablation of cell-mediated immu-
nity [43]. Two recent studies that combined CD8 and
CD20 cell depletion in two different species of AGMs
reported a trend toward a prolongation in peak viremia
that was controlled with the rebound of the CD8+ T cells,
and had no impact on the course of SIVagm infection
[44,45].
In this study, we performed experimental in vivo CD8+
cell depletion in AGMs during acute SIV infection. We
report that CD8+ cell depletion results in a lack of control
of acute viral replication, thus pointing out a role for cel-
lular immune responses in the partial control of acute
viral replication in natural hosts. However, this lack of
control of viral replication did not result in rapid disease
progression, most probably because of the short duration
of CD8+ cell depletion. Thus, our results support the par-
adigm in which cell-mediated immune responses are
involved in a partial control of viral replication in natural
hosts below levels that may trigger the factors responsible
for disease progression (i.e. excessive immune activation,
cell proliferation and apoptosis).
Results
Clinical and serological data
Nine AGMs were infected with SIVagm.sab and serocon-
verted by day 21-28 p.i. (data not shown). Four were
depleted of CD8 cells by use of an anti-CD8 mAb, while 5
served as controls. The dynamics of serological markers
of SIVagm.sab infection was similar between CD8-
depleted AGMs and controls (data not shown). None ofGaufin et al. Retrovirology 2010, 7:42
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the animals developed fever after infection with
SIVagm.sab. No clinical signs of primary infection, weight
loss, opportunistic infection or increase in size of LNs
were observed during the acute phase of infection or later
on. Animals were monitored up to day 225 p.i. when they
were euthanized. No clinical or pathological sign of AIDS
was observed at the necropsy.
cM-T807 mAb treatment successfully depleted CD8+ cells in 
blood and LNs, but lead only to incomplete depletion and 
down regulation of CD8 on cells in the intestine
Administration of 50 mg/kg of cM-T807 at day 0, fol-
lowed by a 10 mg/kg dose at days 6 and 13 p.i resulted in
complete depletion of peripheral CD8+ T cells that was
maintained in the peripheral blood through day 14 p.i. in
three AGMs, while depletion lasted for 28 days in the
fourth AGM receiving the anti-CD8 mAb (Figure 1a,
upper panels). With the exception of partial, transient
CD8+ T cell decline corresponding to the peak of viral
replication, the levels of CD8+ T cells were stable in con-
trols (Figure 1a, upper panels).
In the LNs, depletion of CD8+ cells was not as sustained
as that observed in peripheral blood and lasted less than
14 days in all animals (Figure 1a, lower left panel). In the
intestine, assessment of CD8+ T cell depletion using an
anti-CD8αα MAb showed that CD8+ T cell depletion was
transient and incomplete. CD8+ cells could be detected in
the intestine as early as day 8 p.i. (Figure 1a, lower right
panel). This is in agreement with previous studies in
RMs, for which mucosal CD8 depletion was incomplete
even at high doses of cM-T807 [23,33]. Flow cytometry
analysis of the efficacy of CD8+ T cell depletion using an
anti-CD8αβ MAb confirmed complete depletion in
periphery and lymphoid tissue, and the downregulation
of CD8+ cells in the intestine. Thus, in contrast to control
animals, in which there was no significant change in the
CD8+ T cell population during the follow-up (data not
shown), in CD8-depleted monkeys, cM-T807 administra-
tion resulted in a significant change of CD8+ T cells (Fig-
ure 1b, lower panels). At day 8 p.i., flow cytometry
analysis failed to identify CD8+ T cells in the intestine of
cM-T807-treated monkeys. However, one should note
that at this time point, there was a dramatic increase of
the double negative cell popula tion when compared to
both day 0 p.i. and day 28 p.i. (Figure 1b, lower panels).
This observation strongly suggests a down regulation of
CD8 expression rather than a true complete CD8+ cell
depletion at the mucosal sites.
IHC staining for CD8+ cells in intestinal tissue showed a
significant decline of CD8-expression by cells in both the
Peyer's patches (Figure 2, upper panels) and lamina pro-
pria (Figure 2, lower panels) of the jejunum at day 8 p.i.,
compared to days 0 and 42 p.i. Note that the reduction in
CD8 expression observed by IHC may be the result of the
blockage of CD8 by the cM-T807 antibody, in agreement
with previous report indicating that cM-T807 could also
block the CD8 marker which would result in a loss of
CD8+ cell function in this compartment [23,33] and that
residual CD8+ cells in the intestine may be functionally
inactive.
A decrease in the both the percentages (Figure 3a) and
absolute numbers (data not shown) of CD3+ cells was
observed in both peripheral blood and LNs (Figure 3b),
thus providing further evidence that CD8+ cell depletion
indeed occurred at least partially in lymphoid tissues. In
contrast, the CD3+ cell levels in the intestine were stable
in the cM-T807 treated animals and were in a similar
range as in control animals (Figure 3c), thus pointing
towards either a downregulation of the CD8+ marker or a
blocking by the cM-T807 antibody at mucosal sites.
Impact of CD8+ cell depletion on the control of 
SIVagm.sab92018 replication
The VLs peaked later in CD8-depleted AGMs (days 10-14
p.i.) than in controls (days 8 and 10 p.i.). Peak VLs were
similar between the two groups, ranging from 107 to 108
SIV RNA copies/ml (average: 9.37 ± 1.36 × 107 versus 6.13
± 3.41 × 107 SIV RNA copies/ml, p = 0.078) (Figure 4a).
There was a delay in the post-peak control of viral repli-
cation in the CD8-depleted AGMs compared to controls
and, at day 21 p.i., VLs ranged from 106 to 107 SIVagm.sab
RNA copies/ml (average: 1.16 ± 0.71 × 107 SIVagm.sab
RNA copies/ml) and were of 104 to 106 SIVagm.sab RNA
copies/ml (average: 3.02 ± 2.9 × 105 SIVagm.sab RNA
copies/ml) in controls (p = 0.016) (Figure 4a). Analysis of
the area under the curve of the logarithm of VL showed
that cM-T807-treated AGMs had higher viral replication
than controls at least up to day 29 p.i. (p = 0.016). VLs of
cM-T807-treated AGMs and controls were then similar
at later time points (i.e., 1.14 ± 0.89 × 105 vs 0.69 ± 0.35 ×
105 SIVagm.sab RNA copies/ml at day 100 p.i.) (Figure
4a), coincidental with the appearance of CD8+ cells (Fig-
ure 1a).
SIVagm replication in PBMC showed a similar pattern,
with significantly higher VLs in cM-T807-treated AGMs
compared to controls during early acute infection (Figure
4b), as measured by the area under the logarithm of the
viral levels up to day 29 p.i. (p = 0.016). With the rebound
of CD8+  cells, similar control of viral replication was
observed in both groups (Figure 4b).
Effects of CD8+ cell depletion on other immune cell subsets
W h e n  t h e  a b s o l u t e  c o u n t s  o f  p e r i p h e r a l  C D 4 + T cells
were compared between the CD8+ depleted AGMs and
controls, there was no significant difference between the
two groups (Figure 5a). Animals in both groups experi-Gaufin et al. Retrovirology 2010, 7:42
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Figure 1 Effect of cM-T807 administration on CD8+ T cells of African green monkeys. a. As shown by flow cytometry analysis, the CD8-depleting 
antibody induced complete depletion in peripheral blood for 14-21 days. Both percentage (upper left panel) and absolute (upper right panel) CD8+ 
T cell counts are shown. In the LN, the depletion, although complete was shorter than in periphery (lower left panel), while in the intestine, only a 
transient, incomplete depletion was observed (lower right panel). Red symbols and lines denote CD8-depleted monkeys. Black symbols and lines de-
note the control monkeys. b. Flow-cytometry plots of CD4+ and CD8+ populations (gated on CD3+) in peripheral blood, lymph nodes and intestine 
demonstrate that administration of CD8-depleting mAb determined depletion in periphery and lymphoid tissue and likely induced down regulation/
blocking of CD8 molecule rather than CD8+ cell depletion in the intestine. Thus, in monkeys treated with cM-T807 mAb (lower panels), downregula-
tion of CD8 cells in the gut is suggested by the massive increase in the double negative population at the time of maximum depletion (day 8 p.i.) 
compared to baseline (day 0 p.i.). With the rebound of CD8+ cells, this double negative population vanishes, as illustrated here by a plot on samples 
collected at day 28 p.i.
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enced a transient depletion of CD4+ T cells during the
acute infection, with a rebound to near baseline levels as
they progressed towards the chronic infection (Figure
5a).
As expected, the depletion of CD8+ T cells resulted in
an increase in the percentage of CD4+ T cells in the cM-
T807 treated animals in the peripheral blood (data not
shown) and LNs (Figure 5b), as measured by flow cytom-
etry. Moreover, in the post-acute infection, the absolute
CD4+ T cell counts were slightly higher in the peripheral
blood of CD8-depleted AGMs as compared to controls,
and this corresponded to higher levels of CD4+ T cell pro-
liferation (see below). However, these differences
between the two groups did not reach significance levels.
When we analyzed the CD4+ cell population in the gut, a
similar slope of CD4+ T cell depletion was observed for
the two AGM groups during the first month p.i. (p = 0.16)
(Figure 1b and 5c). Although no significant difference in
the magnitude of acute mucosal CD4+ T cell depletion
was observed, during the chronic infection, there was a
trend toward less mucosal CD4+ T cell restoration in cM-
T807-treated group, probably as a result of higher viral
replication for a longer period of time in this group of
AGMs (Figure 5c).
Dynamics of cells with activated phenotypes
A variety of markers of immune activation, including -
DR, CD25, CD69, and Ki67 was used to determine the
levels of T cell immune activation during depletion of
CD8+  cells. The levels of activated CD4+  T cells (as
defined by MHC class II and CD69 expression) appeared
higher in cM-T807-treated AGMs compared to controls
during the acute infection in peripheral blood (Figure 6a
and data not shown), although this increase did not reach
significance (p > 0.19). These levels returned to near
baseline levels after the set point in both groups.
The dynamics of Ki67+ CD4+ T cells were significantly
different between cM-T807-treated AGMs and controls
during both acute and chronic infection, with signifi-
cantly higher expression of Ki-67 in the CD4+ T cells of
CD8-depleted animals (Figure 6c) throughout the follow-
up.
H i g h  l e v e l s  o f  i m m u n e  a c t i v a t i o n  i n  b o t h  p e r i p h e r a l
blood (Figure 6b) and LNs (data not shown) were
observed for CD8+ T cells rebounding after the cM-T807
treatment, as measured by increased levels in all the acti-
vation markers studied: MHC class II (Figure 6b), CD69,
and CD25 (data not shown). As expected, the rebounding
CD8+ T cells were highly proliferative, as illustrated by
the high expression of Ki-67 (Figure 6d). There was no
Figure 2 Immunohostochemistry assessment of the efficacy of 
CD8 depletion on jejunum. Samples from CD8-depleted AGMs were 
collected at the baseline, at day 8 p.i. and at day 42.p.i. As illustrated, 
CD8+ cells from both Peyer patches (PP) and lamina propria (LP) are de-
pleted/down regulated.
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clear correlation between the levels of virus in the plasma
and the levels of T cell activation and proliferation mark-
ers during the acute phase for any of the animals (e.g., one
animal had higher levels of CD69+ CD4+, CD69+ CD8+,
CD25+ CD8+, and Ki67+ CD8+ cells in comparison to the
other animals in the CD8+ depleted group, but these did
not translate into higher viremia in plasma).
These flow-cytometry data that indicated high levels of
T cell activation and proliferation in cM-T807-treated
AGMs were confirmed by the dynamics of proinflamma-
tory cytokines assessed in plasma (Figure 7a-c). As illus-
trated, the levels of proinflammatory IL-1RA (Figure 7a)
and IL-15 (Figure 7c) were significantly higher in CD8-
depleted AGMs than in controls. IL-12 increased simi-
larly in both depleted and undepleted monkeys during
acute SIVagm infection (Figure 7b). These differences in
cytokine levels were significant during the CD8+  cell
depletion (p < 0.05) and tended to persist longer than the
CD8+  c e l l  d e p l e t i o n .  N o t e  t h a t  t h e  h i g h e r  l e v e l s  o f
immune activation and T cell proliferation detected by
immunophenotypic markers in the CD8+ cell depleted
group, lasted longer than those identified by the dynam-
ics of proinflammatory cytokines.
Figure 4 Dynamics of SIVagm.sab plasma (a) and PBMC (b) vRNA 
loads in cM-T807-treated AGMs and control monkeys. In CD8-de-
pleted AGMs there was a delay in the control of acute viral replication. 
Black symbols and lines denote the control monkeys. Red symbols and 
lines denote CD8-depleted monkeys.
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Collectively, these results indicate that CD8+ cell deple-
tion induces significant increases in activation and prolif-
eration of CD4+ T cells. As mentioned above, the fact that
the increased levels of cell activation and proliferation
persist longer than the CD8+ cell depletion probably indi-
cates that the lack of control of viral replication during
postacute SIVagm.sab infection of cM-T807-treated
AGMs is probably mainly dependent on the availability of
CD8+ cells.
Discussion
We report here that CD8+ T cells are involved in the con-
trol of viral replication during acute SIV infection in nat-
ural African NHP hosts. In vivo CD8+ cell depletion in
AGMs followed by infection with SIVagm.sab resulted in
a change in the pattern of acute viral replication, with the
peak VL usually observed during SIV infection in RMs
and natural hosts being replaced with a plateau of high
VLs that lasted as long as CD8+ T cells were depleted (up
to 21 days p.i.). This high viral replication was controlled
after the rebound of CD8+ cells. Therefore, similar to pre-
vious in vivo CD8+ depletion studies in RMs that identi-
fied the importance of CD8+ T cells in controlling viral
replication and disease progression [20,23-
27,29,30,32,33,46,47], our results indicate that CD8+ T
cells are important for the control of virus replication in
natural hosts, especially during the post acute infection.
Our results point to similar mechanisms of controlling
viral replication between pathogenic infections of
humans and RMs and African NHPs that are natural
hosts of SIVs. However, different from SIVmac-infected
macaques in which CD8+ cell depletion may result in
some cases in a lack of control of viral replication and
rapid disease progression [23], in SIVagm-infected AGMs
Figure 6 Dynamics of CD4+ and CD8+ T cell immune activation (as defined by changes in the expression of MHC class II markers) (a and c) 
and of CD4+ and CD8+ T cell proliferation (as defined by changes in the expression of Ki-67) (c and d) in peripheral blood of CD8-depleted 
AGMs (red lines and dots) and control monkeys (black lines and dots). See text for further detail.
0
10
20
30
40
50
60
70
80
90
0 50 100 150 200 250
AGM D1 AGM D2 AGM D3 AGM D4 AGM C1
AGM C2 AGM C3 AGM C4 AGM C5
0
10
20
30
40
50
60
40 80 120 160 200 240
0
1
2
3
4
5
6
7
40 80 120 160 200 240
0
1
2
3
4
5
6
7
0 7 14 21 28 35
0
10
20
30
40
50
60
0 7 14 21 28 35
0
2
4
6
8
10
12
14
40 80 120 160 200 240
0
10
20
30
40
50
60
70
40 80 120 160 200 240
0
10
20
30
40
50
60
70
0 7 14 21 28 35
0
2
4
6
8
10
12
14
0 7 14 21 28 35
%
H
L
A
-
D
R
+
C
D
4
+
T
 
c
e
l
l
s
%
H
L
A
-
D
R
+
C
D
8
+
T
 
c
e
l
l
s
%
K
i
-
6
7
+
C
D
4
+
T
 
c
e
l
l
s
%
K
i
-
6
7
+
C
D
8
+
T
 
c
e
l
l
s
Day postinfection
Day postinfection
Day postinfection
Day postinfection
ab
c dGaufin et al. Retrovirology 2010, 7:42
http://www.retrovirology.com/content/7/1/42
Page 8 of 13
VLs were controlled in all CD8-depleted monkeys at the
time of the rebound of CD8+ cells; and no case of disease
progression was observed. One may argue that the study
group was small and that in a larger study one may expect
to observe a more complex clinical outcome. However,
based on our previous observations, it is unlikely that
natural hosts would progress to AIDS after such a short
period of time of uncontrolled viral replication. We previ-
ously reported that indeed, progression to AIDS in Afri-
can natural hosts is related to higher set-point replication
levels [4,48], but also that African species show a remark-
able resilience to high viral replication, progression to
AIDS being only described after very long incubation
periods [48]. Therefore, even if significant increases in
VLs were observed in our study, the very short duration
of CD8+ cell depletion precluded disease progression in
AGMs.
The administration of cM-T807 mAb successfully
depleted CD8+ T cells in peripheral blood and LNs and
only partially and for a shorter period in the intestine. At
this site, down-regulation of this cell population was also
observed. Our results are similar to what was previously
reported for RMs [23,33]. It is currently unknown why
the anti-CD8+ cM-T807 mAb is less effective in mucosal
tissues, such as the intestine. Previous attempts to
improve the efficacy of mucosal CD8+  cell depletion
through repeated, increased doses of cM-T807 failed [23],
probably due to increased antibody clearance in the intes-
tine or to antibody blockage from reaching the mucosal
sites [23]. However, these studies demonstrated that the
administration of cM-T807 mAb inhibited the generation
of SIV-specific T cell responses [46].
Our results obtained during acute SIVagm infection of
AGMs are somewhat different from the previous report
on CD8+ cell depletion in SMs during chronic SIVsmm
infection, in which only a relatively modest increase in
plasma VL (1 log or less) was observed [43] and was
attributed to the increase in activating, proliferating
CD4+ T cells [43], rather than to the depletion of CD8+
cells. However, although the increase in viral replication
may have resulted from increased immune activation and
proliferation of CD4+ T cells due to CD8+ cell depletion,
one cannot definitively discard the contribution of CD8+
cell depletion in the rebound of viral replication in chron-
ically SIVsmm-infected SMs. Note that the results
reported in chronically SIVsmm-infected SMs are not
necessarily surprising, as CD8+ depletion performed dur-
ing chronic SIV infection in RMs was less effective than
in SIV-uninfected animals and indicated that CD8+ cell
depletion resulted in modest VL increases, with no signif-
icant impact on disease progression rate [24,25].
Similar to previous reports [43], we also observed sig-
nificant increased levels of Ki-67+ CD4+ T cells for an
extended duration in the CD8+ cell-depleted AGMs com-
pared to controls. However, we believe that the increases
in viral replication occurred as a result of CD8+ T cell
depletion rather than from increased immune activation.
While agreeing that immune activation does play a signif-
icant role in controlling VLs, since we have demonstrated
in vivo that experimental increases in immune activation
Figure 7 Dynamics of plasma proinflammatory cytokine secre-
tion: 1L-1ra (a), IL-12 (b) and IL-15 (c) in CD8-depleted AGMs (red 
lines and dots) and control monkeys (black lines and dots). See 
text for further detail.
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correlate with increases in VLs [14], we also do not wish
to downplay the significance of CD8+ T cells during the
post acute infection. It was impossible in this experimen-
tal setting to separate the roles of immune activation and
CD8+ cell depletion; however, there is evidence that can
be gleaned from our study in relation to the importance
of CD8 cellular immune responses in controlling acute
SIVagm.sab replication: (i) VLs decreased with the reap-
pearance of CD8+  T cells, as previously reported
[23,24,49], while increased levels of immune activation
persisted after the control of viral replication; (ii) no clear
correlation was observed between the levels of immune
activation and the levels of virus replication, and (iii)
finally, in a recent set of experiments performed in SIV-
infected RMs, consisting of dissociation between CD8+
cell depletion and immune activation of CD4+ T cells
(prevented through administration of an anti-IL-15
MAb), a clearer correlation could be established between
CD8+ cell depletion and the lack of control of viral repli-
cation [50].
It was also suggested that the increases in VLs during
the CD8+ cell depletion could also result from the reacti-
vation of latent CMV, which has been suggested to occur
as a result of depletion of CD8+ T cells for an extended
period of time [43]. However, CD8+ cell depletion alone
probably only results in a low-level reactivation of CMV
and is not likely to contribute much to the increase in VLs
observed, as research has indicated that for a high level of
reactivation of CMV to occur, both the humoral and cel-
lular immune responses need to be impaired [51].
Furthermore, because the cM-T807 antibody does not
discriminate between NK cells or CD8+ T cells, it could
also be hypothesized that the elimination of NK cells also
contributed to the rise in VLs. Because cM-T807 targets
the α chain of CD8+ T cells, NK cells (which contain the
CD8α chain) are also depleted [20,32]. Further support of
this argument comes from studies showing that during
the first two weeks of infection, NK cell activity is
increased in SIVmac251 RMs and decreases once the
peak of viremia occurs [52], indicating that the increases
in VL could also be caused by the elimination of NK cells.
However, NK cells have been recently experimentally
depleted in RMs during both the acute and chronic
phases of SIV infection, and no impact on viral replica-
tion was observed [53,54]. Note, however, that in both
these studies the NK-depleting MAb was an anti-CD16
and that not all NKs express CD16 in nonhuman pri-
mates [55]. Therefore, using CD16 as a marker to deplete
NK cells may have underestimated the role of NK cells in
HIV infections.
Even though our results show that depletion of CD8+
cells results in higher levels of viral replication during the
acute SIVagm infection of AGMs, suggesting a role of cel-
lular immune responses in controlling infection in natu-
ral hosts, it is unlikely that cellular immunity is the sole
determinant of the lack of disease progression in natural
hosts. Previous studies have shown that cellular immune
responses in natural hosts are not substantially different
from those observed in pathogenic SIV infection in RMs
[36,37,39,40]. Moreover, combined B and CD8+  cell
depletions (aimed at suppressing adaptive immune
responses during acute SIV infection in AGMs) although
delaying the partial containment of viremia, did not
induce disease in AGMs [44,45], similar to the results
reported here. Numerous studies have shown that during
the long term co-evolution with their species-specific
SIVs, natural hosts have developed a plethora of mecha-
nisms to prevent the deleterious consequences of SIV
infection; most notably the natural hosts can prevent
excessive immune activation, cell proliferation and apop-
tosis during the chronic SIV infection. It is currently con-
sidered that the ability to fine-tune the inflammatory
responses is the main mechanism through which disease
progression can be prevented in natural hosts.
Conclusions
By demonstrating a role of adaptive immune response in
controlling the viral replication to levels that can be toler-
ated by natural hosts without disease progression, our
results point to two major conclusions: first, that an effec-
tive approach for the control of HIV disease progression
is not necessarily based on induction of an excess of adap-
tive immunity, but should be based on a balanced
immune response in conjunction with the control of
immune activation, cell proliferation and apoptosis. Sec-
ond, the lack of disease progression in natural hosts is not
due to "tolerance" of the virus by the host, but actively
achieved with a large arsenal of mechanisms that act to
maintain the virus at levels that can be tolerated without
deleterious consequences. In light of recent vaccine fail-
ures, our results show that a successful vaccine approach
for HIV most likely should consider all these mecha-
nisms.
Methods
Animals
This study included nine Carribean AGMs (Chlorocebus
sabaeus) that were housed at the Tulane National Primate
Research Center (TNPRC), which is an Association for
Assessment and Accreditation of Laboratory Animal
Care (AAALAC) International facility. All animals were
adults ranging from 6-13 years. The animals were fed and
housed according to regulations set forth by the Guide for
the Care and Use of Laboratory Animals [56] and the Ani-
mal W elfare Act. In this study , the animal experimentsGaufin et al. Retrovirology 2010, 7:42
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were approved by the Tulane University Institutional Ani-
mal Care and Use Committee (IACUC).
Anti-CD8 Ab treatments and virus inoculation
All nine AGMs were inoculated intravenously with
plasma corresponding to 300 tissue culture-infective dose
(TCID50) of SIVagm.sab92018 [8]. Four AGMs were
treated intravenously with 50 mg/kg of cM-T807, a
mouse anti-human monoclonal anti-CD8 antibody, at
day 0 and 10 mg/kg on days 6 and 13. The five AGMs not
treated with the monoclonal antibody served as controls
and were inoculated with virus only.
Sampling of blood, LNs and intestine
Blood was collected from all the animals at 3 time points
preinfection (days -35, -14, -7 p.i.), then at the time of
SIVagm.sab inoculation, twice per week for the first two
weeks p.i., weekly for the next four weeks, every two
weeks for the next two months and then every two
months, up to day 225 p.i. LN biopsies were sampled on
days 0, 8, 21, 42, and 225 p.i. Intestinal endoscopies (prox-
imal jejunum) consisting of approximately 10-15, 1-2
mm2 pieces were obtained by endoscopic guided biopsy
were performed on days -18, 0, 8, 21, 29, 42, 56, 72, 100,
and 126 p.i. Intestinal resections (five to ten cm) were
removed surgically from the animals at days -35, 8, and 42
p.i. Additional intestine pieces were obtained at necropsy.
The control animals followed a similar sampling sched-
ule.
Isolation of lymphocytes from blood, LNs, and intestine
Within one hour of blood removal, whole blood was used
for flow cytometry. Plasma was removed from the blood
within two hours of sample removal, aliquoted and stored
in the -80°C until VL testing was performed. PBMCs were
extracted from whole blood using LSM (Organon-Tech-
nica, Durham, NC) by centrifugation. PBMCs were fro-
zen at -80°C using freezing media containing RPMI, heat-
inactivated newborn calf serum, and 10% DMSO.
Lymphocytes were separated from LNs by pressing tis-
sue through a nylon mesh screen. Cells were filtered
through nylon bags, and washed with RPMI media (Cell-
gro, Manassas, VA) containing 5% heat-inactivated FBS,
0.01% Penicillin-Streptomycin, 0.01% L-glutamine, and
0.01% Hepes buffer, as previously described [5,8].
Lymphocytes were separated from pinch biopsies and
resections as previously described [5,14,57,58]. Mononu-
clear cells were separated from the blood through Ficoll
density gradient centrifugation. Briefly, lymphocytes
were isolated from intestinal biopsies using EDTA fol-
lowed by collagenase digestion and Percoll density gradi-
ent centrifugation [5,14,58].
Within 30 minutes after separation, cells were stained
for flow cytometry. Those cells not used for staining were
frozen at -80°C in freezing media.
Flow cytometry analysis of lymphocyte populations
Immunophenotyping of lymphocytes isolated from the
blood, LNs and intestine was performed by using fluores-
cently conjugated monoclonal antibodies in a four-color
staining technique. The samples were run using a Facs-
Calibur flow cytometer (Becton Dickinson) and the data
were analyzed using Cell Quest (Becton Dickinson) and
FlowJo (Tree Star, Inc). The mAbs were conjugated to
FITC, PE, PerCP, or APC. The following mAbs were used
for surface stains: CD3-FITC (clone no. SP34), CD8-PE
(clone no. SK1), CD20-PE (clone no. L27), CD3-PerCP
(clone no. SP34-2), HLA-DR-PerCP (clone no. L243),
CD8α (clone no. SK1), CD4-APC (clone no. L200) (BD
Bioscience) and CD8αβ (clone no. 2ST8.5H7) (Beckman
Coulter). Ki-67-FITC (clone no. B56) was used for intrac-
ellular staining (BD Bioscience). All these mAbs were
cross-reactive for AGMs. Whole blood was lysed using
FACS lysing solution (BD Biosciences) and stained using
a procedure formerly described [8]. Mononuclear cells
from blood, LNs, and intestines were stained using an
excess of monoclonal antibodies by incubation at 4°C for
30 minutes. Cells were then washed (400 g/7 min) with
PBS and fixed with 2% paraformaldehyde. For intracellu-
lar stains, lymphocytes were fixed with 4% paraformalde-
hyde for 1 hour. Cells were then washed with PBS (400 g/
7 min), washed with a 0.1% saponin solution (400 g/7
min), incubated with Ki-67-FITC, washed with a 0.1%
saponin solution, and fixed with a 2% paraformaldehyde
solution. The absolute number of peripheral lymphocytes
was determined by performing cell blood counts on each
blood sample.
Analysis of anti-SIVagm.sab IgG responses
In-house SIVagm.sab-specific PIV-EIA was used for the
titration of anti-gp41 and anti-V3 antibody titers, as
described [59], on serial plasma or serum samples to
investigate the dynamics of anti-SIVagm.sab seroconver-
sion.
Viral load quantification
Plasma VLs were quantified by real-time PCR, as previ-
ously described [8,9,58]. SIVagm.sab RNA loads were also
quantified in mononuclear cells isolated from blood, LNs
and intestinal biopsies using the same real-time PCR
assay [8,9,58]. For tissue quantification, viral RNA was
extracted from 5 × 105-106 cells from PBMCs, LNs and
intestine with RNeasy (Qiagen), and VLs were quantified
as described elsewhere [8,9,58]. Simultaneous quantifica-
tion of RNAse P (RNase P detection kit, Applied Biosys-Gaufin et al. Retrovirology 2010, 7:42
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tems, CA), a single copy gene with 2 copies per diploid
cell, was done to normalize sample variability and allow
accurate quantification of cell equivalents [16,60]. Assay
sensitivity was 10 RNA copies/105 cells and 100 RNA
copies per 1 ml of plasma.
IHC
IHC was performed on LNs and intestinal samples. Fresh
frozen tissues in optimal cutting temperature compound
(OCT) were used. Staining was done using an anti-CD8
mAb (clone SK1 BD Biosciences) and an avidin-biotin
complex HRP technique (Vectastain Elite ABC kit, Vec-
tor laboratories, Burlingame, CA). Sections were visual-
ized with DAB (Dako, Carpinteria, CA) and
counterstained with hematoxylin.
Cytokine determination
Cytokine testing in plasma was done using a sandwich
immunoassay-based protein array system, the Human
Cytokine 25-Plex (Biosource International, Camarillo,
CA, USA), as instructed by the manufacturer and read by
the Bio-Plex array reader (Bio-Rad Laboratories, Hercu-
les, CA, USA) which uses Luminex fluorescent-bead-
based technology (Luminex Corporation, Austin, TX,
USA).
Statistical analysis of data
Data comparisons between AGMs depleted of CD8+ T
cells and controls were done using two-tailed non-para-
metric tests (Mann-Whitney). These tests included anal-
yses of VL, HLA-DR, CD69 and Ki67 over the first weeks
p.i., when the effects of infection were most pronounced
(see "Results"). These variables were analyzed estimating
the areas under the curve by numerical integration of a
spline interpolation of the data (the logarithm for VL to
avoid over-emphasizing the peak of viral infection) using
Mathematica 6.0 (Wolfram Research Inc, IL). The deple-
tion of CD4+ T-cells was analyzed by linear mixed effects
models over the period indicated. Where needed, appro-
priate transformations were applied, so that the assump-
tions of homoscedasticity and normality of residuals were
met. Significance was assessed at the p = 0.05 level, and
analyses were performed using S-Plus 2000 (MathSoft
Inc, MA).
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